CAALL-F01: National Protocol for the Treatment of Childhood and Adolescent Acute Lymphoblastic Leukemia (LAL)

Trial Profile

CAALL-F01: National Protocol for the Treatment of Childhood and Adolescent Acute Lymphoblastic Leukemia (LAL)

Not stated
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Pegaspargase (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CAALL F01
  • Most Recent Events

    • 06 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top